Work

A Combined Biomarker of Peripheral PD-1+ T Cells and Tumor PD-L1 Guides First-Line Treatment Selection in NSCLC: A Prospective Cohort Study

Year: 2026
Type: preprint
Abstract: Background Selecting first-line therapy for advanced non-small cell lung cancer (NSCLC) without driver mutations is challenging due to a lack of predictive biomarkers. Tumor PD-L1 testing is invasive, heterogeneous, and imperfect for identifying patients at risk of hyperprogression. We investigated non-invasive biomarkers to guide treatment choice between chemo-immunotherapy and chemo-antiangiogenic therapy. Methods This prospective cohort study enrolled 66 treatment-naïve patients with metastatic NSCLC. Patients received either first-line chemo-immunotherapy (n = 37) or chemo-antiangiogenic therapy (n = 29). We compared progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The predictive value of tumor PD-L1 expression combined with PD-1 expression on peripheral blood CD4 + and CD8 + T cells was assessed. Results No significant differences were found between the two treatment groups in median PFS (7.9 vs. 9.2 months, P = 0.357), OS (20.8 vs. 19.8 months, P = 0.616), or ORR (32.4% vs. 41.4%, P = 0.623). However, within the chemo-immunotherapy group, patients with high PD-L1 and/or high PD-1 on CD4+/CD8 + T cells had significantly superior PFS (HR 0.18, P = 0.006) and OS. In the chemo-antiangiogenic group, low PD-1 on CD4 + T cells predicted better survival (mOS: 24.9 vs. 9.3 months, P = 0.032). Adverse events were comparable. Conclusion First-line chemo-immunotherapy and chemo-antiangiogenic therapy showed comparable efficacy in an unselected population. A composite biomarker of peripheral PD-1 + T cells and tumor PD-L1 effectively identified patients with superior survival benefits from immunotherapy, offering a promising non-invasive strategy for personalizing initial NSCLC treatment.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7236574399
Cites: 49
Cited by:
Related to: 10